Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ.

PLoS One. 2011 Apr 13;6(4):e18526. doi: 10.1371/journal.pone.0018526.

2.

Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.

Adams WC, Gujer C, McInerney G, Gall JG, Petrovas C, Karlsson Hedestam GB, Koup RA, Loré K.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7499-504. doi: 10.1073/pnas.1017146108. Epub 2011 Apr 18.

3.

CD8 T-cell activation in mice injected with a plasmid DNA vaccine encoding AMA-1 of the reemerging Korean Plasmodium vivax.

Kim HJ, Jung BK, Lee JJ, Pyo KH, Kim TY, Choi BI, Kim TW, Hisaeda H, Himeno K, Shin EH, Chai JY.

Korean J Parasitol. 2011 Mar;49(1):85-90. doi: 10.3347/kjp.2011.49.1.85. Epub 2011 Mar 18.

4.

Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Arévalo-Herrera M, Soto L, Perlaza BL, Céspedes N, Vera O, Lenis AM, Bonelo A, Corradin G, Herrera S.

Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):35-42. doi: 10.4269/ajtmh.2011.09-0507.

5.

Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.

Arévalo-Herrera M, Vera O, Castellanos A, Céspedes N, Soto L, Corradin G, Herrera S.

Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):21-7. doi: 10.4269/ajtmh.2011.10-0110.

6.

Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Herrera S, Fernández OL, Vera O, Cárdenas W, Ramírez O, Palacios R, Chen-Mok M, Corradin G, Arévalo-Herrera M.

Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):12-20. doi: 10.4269/ajtmh.2011.09-0516.

7.

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.

Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.

J Immunol. 2010 Dec 15;185(12):7583-95. doi: 10.4049/jimmunol.1001760. Epub 2010 Nov 22.

8.

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.

Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J.

Clin Vaccine Immunol. 2010 Nov;17(11):1687-94. doi: 10.1128/CVI.00311-10. Epub 2010 Sep 8. Erratum in: Clin Vaccine Immunol. 2011 Feb;18(2):353.

9.

Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.

Sedegah M, Kim Y, Peters B, McGrath S, Ganeshan H, Lejano J, Abot E, Banania G, Belmonte M, Sayo R, Farooq F, Doolan DL, Regis D, Tamminga C, Chuang I, Bruder JT, King CR, Ockenhouse CF, Faber B, Remarque E, Hollingdale MR, Richie TL, Sette A.

Malar J. 2010 Aug 24;9:241. doi: 10.1186/1475-2875-9-241.

10.

A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice.

Gentil F, Bargieri DY, Leite JA, Françoso KS, Patricio MB, Espíndola NM, Vaz AJ, Palatnik-de-Sousa CB, Rodrigues MM, Costa FT, Soares IS.

Vaccine. 2010 Aug 31;28(38):6183-90. doi: 10.1016/j.vaccine.2010.07.017. Epub 2010 Jul 21.

PMID:
20654667
11.

Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.

Bruder JT, Stefaniak ME, Patterson NB, Chen P, Konovalova S, Limbach K, Campo JJ, Ettyreddy D, Li S, Dubovsky F, Richie TL, King CR, Long CA, Doolan DL.

Vaccine. 2010 Apr 19;28(18):3201-10. doi: 10.1016/j.vaccine.2010.02.024. Epub 2010 Feb 25.

PMID:
20188680
12.

Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.

Asefa B, Korokhov N, Lemiale F.

Vaccine. 2010 Apr 30;28(20):3617-24. doi: 10.1016/j.vaccine.2009.12.047. Epub 2010 Jan 4.

PMID:
20051277
13.

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Pierce MA, Ellis RD, Martin LB, Malkin E, Tierney E, Miura K, Fay MP, Marjason J, Elliott SL, Mullen GE, Rausch K, Zhu D, Long CA, Miller LH.

Vaccine. 2010 Mar 2;28(10):2236-42. doi: 10.1016/j.vaccine.2009.12.049. Epub 2010 Jan 4.

14.

High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.

Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, Soisson L, Diggs CL, Heppner DG, Lanar DE, Collins WE, Barnwell JW.

PLoS One. 2009 Dec 3;4(12):e8138. doi: 10.1371/journal.pone.0008138.

15.

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, Imoukhuede E, Jepsen S, Ofori-Anyinam O, Faber B, Kocken CH, Arnold M, Walraven V, Teelen K, Roeffen W, de Mast Q, Ballou WR, Cohen J, Dubois MC, Ascarateil S, van der Ven A, Thomas A, Sauerwein R.

PLoS One. 2008;3(12):e3960. doi: 10.1371/journal.pone.0003960. Epub 2008 Dec 18.

16.

A trial of combination antimalarial therapies in children from Papua New Guinea.

Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM.

N Engl J Med. 2008 Dec 11;359(24):2545-57. doi: 10.1056/NEJMoa0804915. Epub 2008 Dec 8.

17.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.

18.

Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

Iriemenam NC, Khirelsied AH, Nasr A, ElGhazali G, Giha HA, Elhassan A-Elgadir TM, Agab-Aldour AA, Montgomery SM, Anders RF, Theisen M, Troye-Blomberg M, Elbashir MI, Berzins K.

Vaccine. 2009 Jan 1;27(1):62-71. doi: 10.1016/j.vaccine.2008.10.025. Epub 2008 Oct 31.

PMID:
18977268
19.

Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.

Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, Kokwaro G, Aseffa A, Engers H.

Malar J. 2008 Oct 29;7:220. doi: 10.1186/1475-2875-7-220.

20.

A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.

Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, Dubovsky F, Liu J, Wang Q, Pan X, Chen T, Giersing B, Xu Y, Kang X, Gu J, Shen Q, Tucker K, Tierney E, Pan W, Long C, Cao Z.

Vaccine. 2008 Dec 9;26(52):6864-73. doi: 10.1016/j.vaccine.2008.09.081. Epub 2008 Oct 16.

PMID:
18930094
Items per page

Supplemental Content

Write to the Help Desk